Overall response rate Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (any) Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Severe adverse event (grade ≥ 3 ) Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Neonatal mortality · very preterm infants at risk of intraventricular hemorrhage
It is very uncertain whether antithrombin changes neonatal mortality (all‐cause, < 28 days of age) compared with placebo (very low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · preterm infants at risk of intraventricular haemorrhage
Heparin showed no clear difference in severe IVH compared with placebo/no treatment (low certainty).
1 finding from 1 review
Neonatal mortality · preterm infants at risk of intraventricular haemorrhage
Heparin showed no clear difference in neonatal mortality (all‐cause) compared with placebo/no treatment (low certainty).
1 finding from 1 review
Woman's perception of pain (as defined by trialists) · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Woman's perception of pain (as defined by trialists) · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure Feeding interruption, blocking or leakage of the tube, non‐adherence · adult patients with swallowing disturbances
Percutaneous endoscopic gastrostomy may leads to lower treatment failure Feeding interruption, blocking or leakage of the… compared with nasogastric tube feeding (low certainty).
1 finding from 1 review
Mortality irrespective of · adult patients with swallowing disturbances
It is very uncertain whether percutaneous endoscopic gastrostomy changes mortality irrespective of compared with nasogastric tube feeding (very low certainty).
1 finding from 1 review
Pneumonia · adult patients with swallowing disturbances
Percutaneous endoscopic gastrostomy showed no clear difference in pneumonia irrespective of compared with nasogastric tube feeding (low certainty).
1 finding from 1 review
Adverse events irrespective of · adult patients with swallowing disturbances
Percutaneous endoscopic gastrostomy showed no clear difference in adverse events irrespective of compared with nasogastric tube feeding (moderate certainty).
1 finding from 1 review
30‐day mortality Death during the · gastric cancer
It is very uncertain whether drain changes 30‐day mortality Death during the compared with no drain (very low certainty).
1 finding from 1 review
Post‐operative complications · gastric cancer
1 finding from 1 review
Reoperation · gastric cancer
It is very uncertain whether drain changes re‐operations Re‐operations during the compared with no drain (very low certainty).
1 finding from 1 review
Operation time The time from the start to the end of operation. Scale from: 0 to 100. · gastric cancer
1 finding from 1 review
Length of postoperative hospital stay · gastric cancer
1 finding from 1 review
Percentage of participants reaching PASI 75 · people with paediatric psoriasis
Etanercept leads to higher PASI 75 Participants achieving a 75% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PASI 50 · people with paediatric psoriasis
Etanercept leads to higher PASI 50 Participants achieving a 50% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PASI 90 · people with paediatric psoriasis
Etanercept leads to higher PASI 90 Participants achieving a 90% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review